Renoprotective effects of a combined endothelin type A/type B receptor antagonist in experimental malignant hypertension

Metabolism: Clinical and Experimental

Volumn 46, Issue 9, 1997, Pages 1032-1038

  Kohno, Masakazu ^a   Yokokawa, Koji ^b   Yasunari, Kenichi ^b   Kano, Hiroaki ^b   Minami, Mieko ^b   Ueda, Makiko ^b   Tatsumi, Yoshimi ^b   Yoshikawa, Junichi ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; HYDRALAZINE; TAK 044; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULOSCLEROSIS; INTERSTITIAL NEPHRITIS; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY INJURY; KIDNEY MASS; MALE; MALIGNANT HYPERTENSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULSE RATE; RAT; RECEPTOR BLOCKING; SPONTANEOUSLY HYPERTENSIVE RAT; UREA NITROGEN BLOOD LEVEL;

EID: 0030752672     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90274-2     Document Type: Article

References (52)

1. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988
2. Kohno M, Murakawa K, Horio T, et al: Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension 18:93-100, 1991
3. Firth JD, Ratcliffe PJ, Raine AEG, et al: Endothelin: An important factor in acute renal failure. Lancet 2:1179-1181, 1988
4. Tomita K, Ujiie K, Nakanishi T, et al: Plasma endothelin levels in patients with acute renal failure. N Engl J Med 321:1127, 1991 (letter)
5. Kon V, Sugiura M, Fogo A, et al: Glomerular actions of endothelin in vivo. J Clin Invest 83:1762-1767, 1989
6. Kon V, Sugiura M, Inagami T, et al: Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 37:1487-1491, 1990
7. Takeda M, Breyer MD, Noland TD, et al: Endothelin-1 receptor antagonist: Effects of endothelin- and cyclosporine-treated mesangial cells. Kidney Int 42:1713-1719, 1992
8. Kohno M, Yasunari K, Murakawa K, et al: Plasma immunoreactive endothelin-1 in essential hypertension. Am J Med 88:614-618, 1990
9. Schiffrin EL, Larivière R, Li J-S, et al: Deoxycorticosterone acetate plus salt induce overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. II. Hypertension 25:769-773, 1995
10. Schiffrin EL: Endothelin: Potential role in hypertension and vascular hypertrophy. Hypertension 25:1135-1143, 1995
11. Sesako S, Pegram BL, Willis GW, et al: DOCA-salt induced malignant hypertension in spontaneously hypertensive rats. J Hypertens 2:49-54, 1984
12. Goets KL, Wong BC, Medwed JB, et al: Cardiovascular, renal and endocrine responses to intravenous endothelin in conscious dogs. Am J Physiol 225:R1064-R1068, 1988
13. Miller WL, Redfield MM, Burnett JC Jr: Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest 83:317-320, 1989
14. Yokokawa K, Kohno M, Murakawa K, et al: Acute effects of endothelin on renal hemodynamics and blood pressure in anesthetized rats. Am J Hypertens 2:715-717, 1989
15. Murakawa K, Kohno M, Yokokawa K, et al: Endothelin-induced renal vasoconstriction and increase in cytosolic calcium in renal vascular smooth muscle cells. Clin Exp Hypertens A12:1037-1048, 1990
16. Badr KF, Murray JJ, Breyer MD, et al: Mesangial cell, glomerular and renal vascular response to endothelin in the rat kidney: Elucidation of signal transduction pathways. J Clin Invest 83:336-342, 1989
17. + exchange, c-fos expression and mitogenesis in rat mesangial cells. J Clin Invest 83:708-712, 1989
18. Kohno M, Horio T, Yokokawa K, et al: Endothelin modulates the mitogenic effect of PDGF on glomerular mesangial cells. Am J Physiol 266:F894-F900, 1994
19. Ito H, Hirata Y, Adachi S, et al: Endothelin-1 is an autocrine/ paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92:398-403, 1993
20. Ito H, Hiroe M, Hirata Y, et al: Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89:2198-2203, 1994
21. Sakurai T, Yanagisawa M, Takuwa Y, et al: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348:732-735, 1990
22. Sakurai T, Yanagisawa M, Masaki T: Molecular characterization of endothelin receptors. Trends Pharmacol Sci 19:753-757, 1992
23. Clozel M, Gray GA, Breu V, et al: The endothelin ETs receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186:867-873, 1992
24. Betra KV, McNeill JR, Xu Y, et al: ETB receptors on aortic smooth muscle cells of spontaneously hypertensive rats. Am J Physiol 264:C479-C484, 1993
25. Teerlink JR, Breu V, Sprecher U, et al: Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 74:105-114, 1994
26. Moreland SD, McMullen DM, Delaney CL, et al: Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun 184:100-106, 1992
27. Gray GA, Löffler B-M, Clozel M: Characterization of endothelin receptors mediating concentration of rabbit saphenous vein. Am J Physiol 266:H959-H966, 1994
28. Seo B, Oemar BS, Siebenmann R, et al: ETA and ETs receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89:1203-1208, 1994
29. Li JS, Larivière R, Schiffrin EL: Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24:183-188, 1994
30. Schiffrin EL, Sventek P, Li JS, et al: Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 115:1377-1381, 1995
31. Li JS, Schiffrin E: Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens 13:647-652, 1995
32. Kikuchi T, Ohtaki T, Kawata A, et al: Cyclic hexapeptide endothelin receptor antagonists highly potent for both receptor subtypes ETA and ETB. Biochem Biophys Res Commun 200:1708-1712, 1994
33. Ikeda S, Awane Y, Kusumoto K, et al: A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA- and ETB-mediated blood pressure responses in rats. J Pharmacol Exp Ther 270:728-733, 1994
34. Tsujino M, Hirata Y, Eguchi S, et al: Nonselective ETA/ETB receptor antagonist blocks proliferation of rat vascular smooth muscle cells. Life Sci 56:PL449-PL454, 1995
35. Kohno M, Yasunari K, Murakawa K, et al: Effect on atrial natriuretic peptides of chronic treatment with α-methyldopa and hydralazine in spontaneously hypertensive rats. Am J Hypertens 3:111-116, 1990
36. Wallenstein S, Zucker CL, Fleiss JL: Some statistical methods useful in circulation research. Circ Res 47:1-9, 1980
37. Sakamoto J, Sakai S, Hirata Y, et al: Production of endothelin-1 by rat cultured mesangial cells. Biochem Biophys Res Commun 169:462-468, 1990
38. Zoja C, Orisio S, Perico N, et al: Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-β, thrombin, and a thromboxane A2 analogue. Lab Invest 64:16-20, 1991
39. Sakamoto H, Sakai S, Nakamura Y, et al: Regulation of endothelin-1 production in cultured rat mesangial cells. Kidney Int 41:350-355, 1992
40. Kohno M, Horio T, Ikeda M, et al: Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int 42:860-866, 1991
41. Kohno M, Horio T, Ikeda M, et al: Natriuretic peptides inhibit mesangial cell production of endothelin induced by arginine vasopressin. Am J Physiol 33:F678-F683, 1993
42. Kohno M, Yokokawa K, Horio T, et al: Heparin inhibits endothelin-1 production in cultured rat mesangial cells. Kidney Int 45:137-142, 1994
43. Bakris GL, Re RN: Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 264:F937-F942, 1993
44. Bakris G, Fairbanks R, Traish AM: Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest 87:1158-1164, 1991
45. Löffler BM, Breu V, Clozel M: Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 333:108-110, 1993
46. Benigni A, Zoja C, Corona D, et al: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44:440-444, 1993
47. Mino N, Kobayashi M, Nishikibe A, et al: Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol 221:77-83, 1992
48. Sudjarwo SA, Hori M, Takai M, et al: A novel subtype of endothelin B receptor mediating concentration in swine pulmonary vein. Life Sci 51:431-437, 1993
49. 2+ signaling in cultured rat mesangial cells. Life Sci 53:1631-1641, 1993
50. Kusumoto K, Kubo K, Kandori H, et al: Effects of a new endothelin antagonist, TAK-044, on post-ischemic acute renal failure in rats. Life Sci 55:301-310, 1994
51. Larivière R, Deng LY, Day R, et al: Increased endothelin-1 gene expression in the endothelium of coronary arteries and in the endocardium of DOCA-salt hypertensive rats. J Mol Cell Cardiol 27:2123-2131, 1995
52. Kiowski W, Sütsch G, Hunziker P, et al: Evidence for endothelin1-mediated vasoconstriction in severe chronic heart failure. Lancet 346:732-736, 1995